These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12755580)

  • 21. Anticipating the impact of Bruesewitz v. Wyeth on Vaccine And Medical Countermeasure Injury Compensation And Availability.
    Courtney B; Morhard R
    Biosecur Bioterror; 2010 Dec; 8(4):315-20. PubMed ID: 21142760
    [No Abstract]   [Full Text] [Related]  

  • 22. Product liability proposals, Sweden.
    Brahams D
    Lancet; 1990 Oct; 336(8721):997-8. PubMed ID: 1977016
    [No Abstract]   [Full Text] [Related]  

  • 23. Vaccine shortages persist despite lessons from past.
    Traynor K
    Am J Health Syst Pharm; 2004 Dec; 61(23):2458, 2460, 2462. PubMed ID: 15595217
    [No Abstract]   [Full Text] [Related]  

  • 24. Industry perspectives: ensuring vaccination of children and adolescents without financial barriers.
    Feinberg MB; Gordon L
    Pediatrics; 2009 Dec; 124 Suppl 5():S563-4. PubMed ID: 19948589
    [No Abstract]   [Full Text] [Related]  

  • 25. Standards for child and adolescent immunization practices. National Vaccine Advisory Committee.
    National Vaccine Advisory Committee
    Pediatrics; 2003 Oct; 112(4):958-63. PubMed ID: 14523192
    [No Abstract]   [Full Text] [Related]  

  • 26. Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee.
    Santoli JM; Peter G; Arvin AM; Davis JP; Decker MD; Fast P; Guerra FA; Helms CM; Hinman AR; Katz R; Klein JO; Koslap-Petraco MB; Paradiso PR; Schaffner W; Whitley-Williams PN; Williamson DE; Gellin B;
    JAMA; 2003 Dec; 290(23):3122-8. PubMed ID: 14679275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plea to restore public funding for vaccine development.
    Puliyel JM
    Lancet; 2004 Feb; 363(9409):659. PubMed ID: 14987898
    [No Abstract]   [Full Text] [Related]  

  • 28. When vaccine injury claims go to court.
    Stewart AM
    N Engl J Med; 2009 Jun; 360(24):2498-500. PubMed ID: 19516030
    [No Abstract]   [Full Text] [Related]  

  • 29. Vaccine liability and safety revisited.
    Evans G
    Arch Pediatr Adolesc Med; 1998 Jan; 152(1):7-10. PubMed ID: 9452701
    [No Abstract]   [Full Text] [Related]  

  • 30. Public health. U.S. vaccine supply falls seriously short.
    Cohen J
    Science; 2002 Mar; 295(5562):1998-2001. PubMed ID: 11896251
    [No Abstract]   [Full Text] [Related]  

  • 31. Global vaccine project gets a shot in the arm.
    Check E
    Nature; 2005 Jan; 433(7024):345. PubMed ID: 15674258
    [No Abstract]   [Full Text] [Related]  

  • 32. European Court of Justice ruling on vaccine liability and its implications for the United States.
    Yang YT
    Vaccine; 2017 Dec; 35(48 Pt B):6583-6584. PubMed ID: 29061348
    [No Abstract]   [Full Text] [Related]  

  • 33. US advisory panel urges government to subsidise vaccine costs. Recommendations would increase vaccination rates and stimulate research and development.
    Ault A
    Lancet; 2003 Aug; 362(9383):539. PubMed ID: 12932398
    [No Abstract]   [Full Text] [Related]  

  • 34. The National Vaccine Injury Compensation Program.
    Cook KM; Evans G
    Pediatrics; 2011 May; 127 Suppl 1():S74-7. PubMed ID: 21502255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. World Vaccine Congress 2008.
    Kilpatrick LE
    IDrugs; 2008 Jul; 11(7):475-7. PubMed ID: 18600590
    [No Abstract]   [Full Text] [Related]  

  • 36. Overcoming liability concerns in vaccine trials involving pregnant women.
    Kaposy C; Lafferty L
    Account Res; 2012 May; 19(3):156-74. PubMed ID: 22686632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives. The great American vaccine shortage.
    Wash Rep Med Health; 1985 Jan; 39(2):suppl 4p. PubMed ID: 10269590
    [No Abstract]   [Full Text] [Related]  

  • 38. Should the vaccine injury compensation program be expanded to cover adults?
    Lloyd-Puryear MA; Ball LK; Benor D
    Public Health Rep; 1998; 113(3):236-42. PubMed ID: 9633868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Who will pay for the adverse events resulting from smallpox vaccination? Liability and compensation issues.
    Strongin RJ; Salinsky E
    NHPF Issue Brief; 2003 Mar; (788):1-15. PubMed ID: 12650125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing.
    Breslow LH
    Harvard J Legis; 2003; 40(1):133-93. PubMed ID: 16594116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.